1-17 of 17
Glenn Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Kari B. Wisinski, Amye J. Tevaarwerk, Mark E. Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C. Bell, Jill M. Kolesar, Christopher Flynn, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2659–2667.
https://doi.org/10.1158/1078-0432.CCR-15-2365
Published: 31 May 2016
View article titled, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer
Open the PDF for Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer in another window
Journal Articles

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, Eric Bradley, Isabel Pohlkamp, Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3692–3704.
https://doi.org/10.1158/1078-0432.CCR-14-0169
Published: 14 July 2014
View article titled, Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

Glenn Liu, Robert Jeraj, Matt Vanderhoek, Scott Perlman, Jill Kolesar, Michael Harrison, Urban Simoncic, Jens Eickhoff, Lakeesha Carmichael, Bo Chao, Rebecca Marnocha, Percy Ivy, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7634–7644.
https://doi.org/10.1158/1078-0432.CCR-11-1677
Published: 18 December 2011
View article titled, Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
Open the PDF for Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate in another window
Journal Articles

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Dana Rathkopf, Glenn Liu, Michael A. Carducci, Mario A. Eisenberger, Aseem Anand, Michael J. Morris, Susan F. Slovin, Yasutsuna Sasaki, Shunji Takahashi, Seiichiro Ozono, Nga Kit Eliza Fung, Shinta Cheng, Jinping Gan, Marco Gottardis, Mary T. Obermeier, Jyotsna Reddy, Steven Zhang, Blisse J. Vakkalagadda, Leila Alland, George Wilding, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 880–887.
https://doi.org/10.1158/1078-0432.CCR-10-2955
Published: 15 February 2011
View article titled, Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Glenn Liu, W. Kevin Kelly, George Wilding, Lance Leopold, Kimberli Brill, Bradley Somer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3172–3176.
https://doi.org/10.1158/1078-0432.CCR-08-2985
Published: 30 April 2009
View article titled, An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Open the PDF for An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer in another window
Journal Articles

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Amye J. Tevaarwerk, Kyle D. Holen, Dona B. Alberti, Carolyn Sidor, Jamie Arnott, Check Quon, George Wilding, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1460–1465.
https://doi.org/10.1158/1078-0432.CCR-08-1599
Published: 19 February 2009
View article titled, Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Open the PDF for Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies in another window
Journal Articles

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle Holen, Garry Schwartz, Mark Albertini, Geoffrey Weiss, Salim Yazji, Chee Ng, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7924–7929.
https://doi.org/10.1158/1078-0432.CCR-08-0378
Published: 01 December 2008
View article titled, Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α<sub>5</sub>β<sub>1</sub> Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
Open the PDF for Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α<sub>5</sub>β<sub>1</sub> Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study in another window
Journal Articles

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Elisabeth I. Heath, David W. Hillman, Ulka Vaishampayan, Shijie Sheng, Fazlul Sarkar, Felicity Harper, Melvin Gaskins, Henry C. Pitot, Winston Tan, S. Percy Ivy, Roberto Pili, Michael A. Carducci, Charles Erlichman, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7940–7946.
https://doi.org/10.1158/1078-0432.CCR-08-0221
Published: 01 December 2008
View article titled, A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Open the PDF for A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer in another window
Journal Articles

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Keith T. Flaherty, Joan Schiller, Lynn M. Schuchter, Glenn Liu, David A. Tuveson, Maryann Redlinger, Chetan Lathia, Chenghua Xia, Oana Petrenciuc, Sunil R. Hingorani, Michael A. Jacobetz, Patricia A. Van Belle, David Elder, Marcia S. Brose, Barbara L. Weber, Mark R. Albertini, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4836–4842.
https://doi.org/10.1158/1078-0432.CCR-07-4123
Published: 01 August 2008
View article titled, A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Open the PDF for A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel in another window
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

Glenn Liu, Jill Kolesar, Douglas G. McNeel, Catherine Leith, Kathy Schell, Jens Eickhoff, Fred Lee, Anne Traynor, Rebecca Marnocha, Dona Alberti, James Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-07-1490
Published: 01 May 2008
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

Steven Attia, Jens Eickhoff, George Wilding, Douglas McNeel, Jules Blank, Harish Ahuja, Alcee Jumonville, Michael Eastman, Daniel Shevrin, Michael Glode, Dona Alberti, Mary Jane Staab, Dottie Horvath, Jane Straus, Rebecca Marnocha, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2437–2443.
https://doi.org/10.1158/1078-0432.CCR-07-4274
Published: 15 April 2008
View article titled, Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Open the PDF for Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer in another window
Journal Articles

Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group

Robert Gray, Judith Manola, Scott Saxman, John Wright, Jan Dutcher, Michael Atkins, Michael Carducci, William See, Christopher Sweeney, Glenn Liu, Mark Stein, Robert Dreicer, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 1966–1969.
https://doi.org/10.1158/1078-0432.CCR-05-1136
Published: 11 April 2006
View article titled, Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group
Open the PDF for Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group in another window
Journal Articles

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

Christopher Sweeney, Glenn Liu, Constantin Yiannoutsos, Jill Kolesar, Dorothea Horvath, Mary Jane Staab, Karen Fife, Victoria Armstrong, Anthony Treston, Carolyn Sidor, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6625–6633.
https://doi.org/10.1158/1078-0432.CCR-05-0440
Published: 15 September 2005
View article titled, A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer
Open the PDF for A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

Glenn Liu, David R. Gandara, Primo N. Lara, Jr., Derek Raghavan, James H. Doroshow, Przemyslaw Twardowski, Philip Kantoff, William Oh, KyungMann Kim, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 924–928.
https://doi.org/10.1158/1078-0432.CCR-03-0050
Published: 10 February 2004
View article titled, A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
Open the PDF for A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer in another window
Journal Articles

Phase II Study of 1α-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer

Glenn Liu, George Wilding, Mary Jane Staab, Dorthea Horvath, Kelly Miller, Amy Dresen, Dona Alberti, Rhoda Arzoomanian, Rick Chappell, Howard H. Bailey
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4077–4083.
Published: 30 September 2003
View article titled, Phase II Study of 1α-Hydroxyvitamin D<sub>2</sub> in the Treatment of Advanced Androgen-independent Prostate Cancer
Open the PDF for Phase II Study of 1α-Hydroxyvitamin D<sub>2</sub> in the Treatment of Advanced Androgen-independent Prostate Cancer in another window
Journal Articles

Phase I Trial of 1α-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer

Glenn Liu, Kurt Oettel, Gregory Ripple, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Arzoomanian, Rebecca Marnocha, Reginald Bruskewitz, Richard Mazess, Charles Bishop, Abhik Bhattacharya, Howard Bailey, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2820–2827.
Published: 01 September 2002
View article titled, Phase I Trial of 1α-Hydroxyvitamin D<sub>2</sub> in Patients with Hormone Refractory Prostate Cancer
Open the PDF for Phase I Trial of 1α-Hydroxyvitamin D<sub>2</sub> in Patients with Hormone Refractory Prostate Cancer in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Oral Penclomedine (NSC 338720) in Adults with Advanced Solid Malignancy

Glenn Liu, Jordan Berlin, Kendra D. Tutsch, Lynn Van Ummersen, Amy Dresen, Rebecca Marnocha, Rhoda Arzomanian, Dona Alberti, Chris Feierabend, Kimberly Binger, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 706–711.
Published: 01 March 2002
View article titled, Phase I Clinical and Pharmacokinetic Study of Oral Penclomedine (NSC 338720) in Adults with Advanced Solid Malignancy
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Oral Penclomedine (NSC 338720) in Adults with Advanced Solid Malignancy in another window